Kodiak Sciences Scraps Late-Stage Vision Loss Biologic

Kodiak Sciences shares fell over 50% on Monday after the company announced that its late-stage biologic failed to sufficiently improve the vision of patients with diabetes macular edema and that it would not be pursuing this program any further.